NASDAQ:BCEL Atreca (BCEL) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free BCEL Stock Alerts $0.08 -0.01 (-11.76%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$0.07▼$0.0950-Day Range$0.06▼$0.3352-Week Range$0.05▼$1.35Volume322,044 shsAverage Volume8.69 million shsMarket Capitalization$2.97 millionP/E RatioN/ADividend YieldN/APrice Target$10.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Atreca alerts: Email Address Atreca MarketRank™ Stock AnalysisAnalyst RatingHold2.20 Rating ScoreUpside/Downside14,233.3% Upside$10.75 Price TargetShort InterestHealthy0.37% of Shares Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews Sentiment1.42Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.61) to ($0.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.57 out of 5 stars 3.1 Analyst's Opinion Consensus RatingAtreca has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.75, Atreca has a forecasted upside of 14,233.3% from its current price of $0.08.Amount of Analyst CoverageAtreca has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.37% of the outstanding shares of Atreca have been sold short.Short Interest Ratio / Days to CoverAtreca has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Atreca has recently decreased by 45.73%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAtreca does not currently pay a dividend.Dividend GrowthAtreca does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAtreca has received a 72.67% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Basic medical research services", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Atreca is -0.85. Previous Next 3.0 News and Social Media Coverage News SentimentAtreca has a news sentiment score of 1.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Atreca this week, compared to 0 articles on an average week.Search InterestOnly 7 people have searched for BCEL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Atreca to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Atreca insiders have not sold or bought any company stock.Percentage Held by Insiders11.30% of the stock of Atreca is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 37.47% of the stock of Atreca is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Atreca are expected to grow in the coming year, from ($1.61) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atreca is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atreca is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtreca has a P/B Ratio of 0.04. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTICBOE shift unlocks new weekend income strategyYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. You're probably wondering, “Okay… But how does that affect me?” This perk now allows everyday traders like yourself to target extra income over the weekend. Check out this training for the full story! About Atreca Stock (NASDAQ:BCEL)Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.Read More BCEL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCEL Stock News HeadlinesMarch 28, 2024 | americanbankingnews.comAtreca, Inc. (NASDAQ:BCEL) Short Interest UpdateFebruary 18, 2024 | wsj.comAtreca Inc. Cl AMarch 28, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionFebruary 15, 2024 | benzinga.comAtreca Stock (NASDAQ:BCEL), Short Interest ReportFebruary 7, 2024 | msn.comAtreca Inc Announces Executive Departures and Consulting AgreementsDecember 29, 2023 | bizjournals.comImmunome to buy assets from California biotech companyDecember 26, 2023 | tmcnet.comBCEL Stock Alert: Halper Sadeh LLC Is Investigating Atreca, Inc.December 21, 2023 | thestreet.comAtreca Inc.March 28, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionDecember 11, 2023 | benzinga.comAtreca Stock (NASDAQ:BCEL) Dividends: History, Yield and DatesNovember 16, 2023 | morningstar.comAtreca Inc Class A BCELNovember 14, 2023 | marketwatch.comAtreca to Cut About 40% of WorkforceNovember 14, 2023 | finance.yahoo.comAtreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic AlternativesNovember 2, 2023 | es.investing.comAtreca Inc (BCEL)October 24, 2023 | finance.yahoo.comBAKER BROS. ADVISORS LP Reduces Stake in Atreca IncOctober 12, 2023 | benzinga.comWhat's Going On With Atreca Inc Stock?October 12, 2023 | bizjournals.comMid-Peninsula building rode biotech's boom. Now it's showing how to survive the bustSeptember 21, 2023 | finance.yahoo.comAtreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb CrossAugust 11, 2023 | msn.comHC Wainwright & Co. Downgrades Atreca Inc - (BCEL)August 11, 2023 | msn.comStifel Downgrades Atreca Inc - (BCEL)August 11, 2023 | finance.yahoo.comAtreca Reports Second Quarter 2023 Financial Results and Announces Corporate RestructuringAugust 2, 2023 | msn.comAtreca Inc - (BCEL) Price Target Increased by 11.89% to 10.20June 20, 2023 | msn.comAtreca Approaches A Major Go/No-Go DecisionJune 6, 2023 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Atreca (BCEL)June 5, 2023 | msn.comHC Wainwright & Co. Reiterates Atreca Inc - (BCEL) Buy RecommendationJune 5, 2023 | finance.yahoo.comAtreca Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors during Oral Abstract Session at the ASCO 2023 Annual MeetingJune 5, 2023 | markets.businessinsider.comAtreca (BCEL) Gets a Buy from H.C. WainwrightSee More Headlines Receive BCEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atreca and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2021Today3/28/2024Next Earnings (Estimated)4/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BCEL CUSIPN/A CIK1532346 Webwww.atreca.com Phone(650) 595-2595FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$10.75 High Stock Price Target$25.00 Low Stock Price Target$4.00 Potential Upside/Downside+14,233.3%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-97,160,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-157.90% Return on Assets-71.39% Debt Debt-to-Equity RatioN/A Current Ratio1.58 Quick Ratio1.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.01 per share Price / Book0.04Miscellaneous Outstanding Shares39,620,000Free Float35,146,000Market Cap$2.97 million OptionableOptionable Beta1.17 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. John A. Orwin M.B.A. (Age 59)President, CEO, Director & Principal Financial Officer Comp: $927.03kDr. Tito A. Serafini Ph.D. (Age 61)Founder & Director Comp: $665.5kMr. Rick Ruiz (Age 60)Principal Accounting Officer Ms. Courtney J. Phillips J.D. (Age 49)General Counsel & Corporate Secretary Roger Richard RuizVice President of FinanceKey CompetitorsPainReformNASDAQ:PRFXOnconetixNASDAQ:ONCOAraviveNASDAQ:ARAVPetros PharmaceuticalsNASDAQ:PTPIPhaseBio PharmaceuticalsNASDAQ:PHASView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 419,623 shares on 3/11/2024Ownership: 2.295%Vanguard Group Inc.Sold 419,623 shares on 2/15/2024Ownership: 2.295%Simplex Trading LLCBought 600 shares on 2/2/2024Ownership: 0.000%Bros. Advisors Lp BakerSold 274,739 sharesTotal: $109,895.60 ($0.40/share)Tito SerafiniSold 5,487 sharesTotal: $5,212.65 ($0.95/share)View All Insider TransactionsView All Institutional Transactions BCEL Stock Analysis - Frequently Asked Questions Should I buy or sell Atreca stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Atreca in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BCEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BCEL, but not buy additional shares or sell existing shares. View BCEL analyst ratings or view top-rated stocks. What is Atreca's stock price target for 2024? 5 brokers have issued 12-month price objectives for Atreca's shares. Their BCEL share price targets range from $4.00 to $25.00. On average, they expect the company's stock price to reach $10.75 in the next year. This suggests a possible upside of 14,233.3% from the stock's current price. View analysts price targets for BCEL or view top-rated stocks among Wall Street analysts. How have BCEL shares performed in 2024? Atreca's stock was trading at $0.1320 at the beginning of the year. Since then, BCEL shares have decreased by 43.2% and is now trading at $0.0750. View the best growth stocks for 2024 here. Are investors shorting Atreca? Atreca saw a decline in short interest in March. As of March 15th, there was short interest totaling 148,000 shares, a decline of 45.7% from the February 29th total of 272,700 shares. Based on an average trading volume of 8,350,000 shares, the days-to-cover ratio is presently 0.0 days. View Atreca's Short Interest. When is Atreca's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024. View our BCEL earnings forecast. How were Atreca's earnings last quarter? Atreca, Inc. (NASDAQ:BCEL) issued its quarterly earnings results on Tuesday, November, 2nd. The company reported ($0.74) EPS for the quarter, meeting analysts' consensus estimates of ($0.74). What is John Orwin's approval rating as Atreca's CEO? 6 employees have rated Atreca Chief Executive Officer John Orwin on Glassdoor.com. John Orwin has an approval rating of 100% among the company's employees. This puts John Orwin in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 90.0% of employees surveyed would recommend working at Atreca to a friend. What other stocks do shareholders of Atreca own? Based on aggregate information from My MarketBeat watchlists, some companies that other Atreca investors own include Alector (ALEC), Editas Medicine (EDIT), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Homology Medicines (FIXX), Akero Therapeutics (AKRO), Hookipa Pharma (HOOK), Lumentum (LITE), TCR2 Therapeutics (TCRR) and Precision BioSciences (DTIL). When did Atreca IPO? Atreca (BCEL) raised $126 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Cowen, Evercore ISI and Stifel served as the underwriters for the IPO and Canaccord Genuity and Brookline Capital Markets were co-managers. Who are Atreca's major shareholders? Atreca's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.30%), Vanguard Group Inc. (2.30%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bros Advisors Lp Baker, John A Orwin, Phillips Courtney and Tito Serafini. View institutional ownership trends. How do I buy shares of Atreca? Shares of BCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BCEL) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atreca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.